Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation Publication Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation Certara2017 年 11 月 30 日
Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies Publication Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies Certara2017 年 11 月 1 日
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach Publication Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach Certara2017 年 9 月 15 日
Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types Publication Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types Certara2017 年 8 月 1 日
Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients Publication Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients Certara2017 年 7 月 15 日
Predicting Diclofenac Systemic and Synovial Fluid Concentrations After Dermal Application Using the Multi-phase Multi-layer MechDermA PBPK Model Poster Predicting Diclofenac Systemic and Synovial Fluid Concentrations After Dermal Application Using the Multi-phase Multi-layer MechDermA PBPK Model Certara2017 年 6 月 6 日
Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response Publication Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response Certara2017 年 6 月 1 日
Obeticholic Acid—From PK Model to Drug Label On-Demand Webinar Obeticholic Acid—From PK Model to Drug Label Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…Certara2017 年 6 月 1 日
Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications Publication Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications Certara2017 年 5 月 1 日
Effect of Disease-related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats Publication Effect of Disease-related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats Certara2017 年 5 月 1 日
